↓ Skip to main content

Dove Medical Press

Neurotherapeutic activity of the recombinant heat shock protein Hsp70 in a model of focal cerebral ischemia in rats

Overview of attention for article published in Drug Design, Development and Therapy, May 2014
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age
  • Above-average Attention Score compared to outputs of the same age and source (53rd percentile)

Mentioned by

googleplus
1 Google+ user

Citations

dimensions_citation
31 Dimensions

Readers on

mendeley
28 Mendeley
Title
Neurotherapeutic activity of the recombinant heat shock protein Hsp70 in a model of focal cerebral ischemia in rats
Published in
Drug Design, Development and Therapy, May 2014
DOI 10.2147/dddt.s62024
Pubmed ID
Authors

Maxim A Shevtsov, Boris P Nikolaev, Ludmila Y Yakovleva, Anatolii V Dobrodumov, Anastasiy S Dayneko, Alexey A Shmonin, Timur D Vlasov, Elena V Melnikova, Alexander D Vilisov, Irina V Guzhova, Alexander M Ischenko, Anastasiya L Mikhrina, Oleg V Galibin, Igor V Yakovenko, Boris A Margulis

Abstract

Recombinant 70 kDa heat shock protein (Hsp70) is an antiapoptotic protein that has a cell protective activity in stress stimuli and thus could be a useful therapeutic agent in the management of patients with acute ischemic stroke. The neuroprotective and neurotherapeutic activity of recombinant Hsp70 was explored in a model of experimental stroke in rats. Ischemia was produced by the occlusion of the middle cerebral artery for 45 minutes. To assess its neuroprotective capacity, Hsp70, at various concentrations, was intravenously injected 20 minutes prior to ischemia. Forty-eight hours after ischemia, rats were sacrificed and brain tissue sections were stained with 2% triphenyl tetrazolium chloride. Preliminary treatment with Hsp70 significantly reduced the ischemic zone (optimal response at 2.5 mg/kg). To assess Hsp70's neurotherapeutic activity, we intravenously administered Hsp70 via the tail vein 2 hours after reperfusion (2 hours and 45 minutes after ischemia). Rats were then kept alive for 72 hours. The ischemic region was analyzed using a high-field 11 T MRI scanner. Administration of the Hsp70 decreased the infarction zone in a dose-dependent manner with an optimal (threefold) therapeutic response at 5 mg/kg. Long-term treatment of the ischemic rats with Hsp70 formulated in alginate granules with retarded release of protein further reduced the infarct volume in the brain as well as apoptotic area (annexin V staining). Due to its high neurotherapeutic potential, prolonged delivery of Hsp70 could be useful in the management of acute ischemic stroke.

Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 28 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 28 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 10 36%
Student > Ph. D. Student 3 11%
Student > Doctoral Student 2 7%
Student > Bachelor 2 7%
Lecturer 2 7%
Other 8 29%
Unknown 1 4%
Readers by discipline Count As %
Neuroscience 7 25%
Biochemistry, Genetics and Molecular Biology 6 21%
Medicine and Dentistry 6 21%
Agricultural and Biological Sciences 3 11%
Nursing and Health Professions 1 4%
Other 1 4%
Unknown 4 14%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 17 June 2014.
All research outputs
#17,285,668
of 25,373,627 outputs
Outputs from Drug Design, Development and Therapy
#1,105
of 2,268 outputs
Outputs of similar age
#146,157
of 242,178 outputs
Outputs of similar age from Drug Design, Development and Therapy
#18
of 39 outputs
Altmetric has tracked 25,373,627 research outputs across all sources so far. This one is in the 21st percentile – i.e., 21% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,268 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.1. This one is in the 42nd percentile – i.e., 42% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 242,178 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 30th percentile – i.e., 30% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 39 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 53% of its contemporaries.